Strange attitude @harvett. I can't imagine there is strategy behind this downramping so I assume it's personal from the Novogen days? Don't let that cloud your investing. This is still a life-changing entry price - take a position!
Do you seriously think they could not get funding and approval for a Phase 2/3 in a heartbeat if they wanted to? It's actually a completely rational and deliberate strategy to hit multiple phase 1/2s across the various combinations. NOX could afford maybe one reasonably sized phase 2 trial without serious dilution, and then if successful, would seriously undervalue Veyonda.
Strange attitude @harvett. I can't imagine there is strategy...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
